Origami Therapeutics develops protein degraders for Huntington's disease
Its ORICISION platform clears mutant huntingtin differently than PROTACs; a collaboration with Ipsen was announced.
See the latest news and media coverage for Origami Therapeutics. We track all announcements, press releases, and industry mentions in real time, all in one place.
Developer of protein degraders and correctors
origamitherapeutics.comLast updated
In short: Origami Therapeutics established a global collaboration with Ipsen and won the 2024 BioChallenge for its neurodegenerative disease work.
Its ORICISION platform clears mutant huntingtin differently than PROTACs; a collaboration with Ipsen was announced.
They advance a small-molecule protein degrader for a rare neurodegenerative disorder using ORICISION™ technology.
Ipsen obtains exclusive option to license Origami's protein degrader program for a rare neurodegenerative disorder. Ipsen would handle global development upon exercising the option.
The company is named a prize winner at the New Orleans BioInnovation Center 2024 BioChallenge. It feels proud and inspired to strive for patients.
Origami Therapeutics, a biotech company developing small molecule protein degraders and conformation correctors to treat neurodegenerative diseases, today announced a global collaboration and option agreement...
Track Origami Therapeutics and your other target companies to get real-time alerts and weekly summaries delivered straight to your inbox.
Browse news for competitors to Origami Therapeutics and other trending companies.